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Abstract
Purpose The objective of this article is to present a new
method for the diagnosis of insulinoma with the use of
[Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4.
Methods Studies were performed in 11 patients with negative
results of all available non-isotopic diagnostic methods (8
with symptoms of insulinoma, 2 with malignant insulinoma
and 1 with nesidioblastosis). In all patients glucagon-like
peptide-1 (GLP-1) receptor imaging (whole-body and single
photon emission computed tomography/CT examinations)
after the injection of 740 MBq of the tracer was performed.
Results Both sensitivity and specificity of GLP-1 receptor
imaging were assessed to be 100 % in patients with benign
insulinoma. In all eight cases with suspicion of insulinoma a
focal uptake in the pancreas was found. In six patients surgical
excision of the tumour was performed (type G1 tumours were
confirmed histopathologically). In one patient surgical treat-
ment is planned. One patient was disqualified from surgery. In
one case with malignant insulinoma pathological accumula-
tion of the tracer was found only in the region of local
recurrence. The GLP-1 study was negative in the other ma-
lignant insulinoma patient. In one case with suspicion of
nesidioblastosis, a focal accumulation of the tracer was ob-
served and histopathology revealed coexistence of insulinoma
and nesidioblastosis.
Conclusion [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exen-
din-4 seems to be a promising diagnostic tool in the localiza-
tion of small insulinoma tumours, but requires verification in a
larger series of patients.
Keywords Insulinoma . GLP-1 . Imaging . Labelled
peptides
Introduction
Overexpression of somatostatin receptors on the neuro-
endocrine tumour cell surface is a very well-known
phenomenon, but not all neoplasms demonstrate a high
incidence of this receptor subtype. Therefore, there is a need to
search for other peptide analogues for diagnostic and thera-
peutic purposes.
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Insulinoma is the most common hormone-secreting neo-
plasm localized in the pancreas. In the majority of cases the
tumours are benign. Their malignant form is observed in
less than 10.0 % of insulinoma patients. Most often insuli-
noma appears as a singular lesion located in the pancreatic
parenchyma (97.0 %), but rarely it might also be multifocal
[1]. A clinically accepted method for the diagnosis of insu-
linoma is the positive result of a 72-h fasting test with a high
insulin level (over 6.0 μIU/ml), elevated C-peptide level
(over 200.0 pmol/l) and absence of sulfonylurea in the
plasma [2]. Similar results also occur in cases of nesidio-
blastosis [1]. Due to the usually small sizes of insulinoma
lesions and the technical limitations of the majority of
standard diagnostic modalities, its anatomic localization is
sometimes difficult. In some cases not only multiphase
contrast-enhanced computer tomography (CT), magnetic
resonance imaging (MRI) or standard ultrasound (US), but
even endoscopic ultrasound (EUS) is not sensitive enough
to visualize the tumour. The sensitivity of EUS for the
detection of insulinoma lesions in the pancreatic head, body
and tail was reported to be 92.6, 78.9 and 40.0 %, respec-
tively [3]. However, other authors reported a higher sensi-
tivity and specificity for the localization of intrapancreatic
lesions by EUS (93.0 and 95.0 %, respectively) [4]. Techni-
ques such as selective arteriography, transhepatic peri-
pancreatic venous blood sampling (TPVB), intra-arterial
calcium stimulation test (ASVS) and intraoperative US
revealed better sensitivity (95.0 %), but are much more
time-consuming and of course invasive [5]. Nuclear medi-
cine imaging, such as somatostatin receptor scintigraphy
(SRS), is positive in about 50.0–60.0 % of benign insulino-
mas [1, 2]. Surgery remains the only method for full recov-
ery of insulinoma patients, but requires precise location of
neoplasm foci. After a successful surgical therapy, a very good
long-term survival outcome is being observed in patients with
insulinoma [2, 6]. For these reasons more sensitive diagnostic
options are required.
Glucagon-like peptide-1 (GLP-1) receptors have been
found in normal organs such as pancreas, blood vessels,
stomach or parafollicular C cells. GLP-1 receptor expression
is also observed on different types of neoplastic cells (e.g.
benign insulinoma, phaeochromocytoma, gastrinoma, para-
ganglioma, pulmonary neuroendocrine tumours and medul-
lary thyroid carcinoma). According to Reubi and co-workers
the density of GLP-1 receptors is extremely high especially
on benign insulinoma cell surfaces. They have been found
in almost 100 % of insulinoma cases—in contradistinction
to ileal carcinoids, where GLP-1 receptor expression was
found only in one third of cases with a heterogeneous
distribution. Somatostatin receptors were detected in two
thirds of examined insulinomas (mainly SSTR1, SSTR2
and SSTR5) [7]. Comparable results were reported by
Bertherat et al. [8]. Therefore, in the near future GLP-1
receptor imaging may become a preferred diagnostic meth-
od for the localization of insulinomas hardly detectable by
other examinations [7].
The first study with a labelled GLP-1 analogue
{[Lys40(Ahx-DTPA-111In)NH2]-exendin-4} was success-
fully performed by Wild et al. in two patients with insuli-
noma [9]. Exendin-4 is a 39-amino acid peptide hormone
originally found in the saliva of the Gila monster, which has
been proved to be a long-acting potent agonist for GLP-1
receptors. A subsequent clinical study with the same 111In-
labelled GLP-1 receptor agonist confirmed the high sensitivity
of this method. In all examined patients benign insulinomas
were detected (six of six) [10]. The same group of scientists
used [Lys40(Ahx-HYNIC/EDDA)NH2]-exendin-4 labelled
with 99mTc for the first time in a mouse model [11]. The use
of 99mTc may improve the quality of images and radiation
safety for patients and the staff by many procedural advan-
tages related to the physical properties of this isotope.
The aim of this paper is to evaluate the clinical usefulness
of the new radiopharmaceutical [Lys40(Ahx-HYNIC-99mTc/
EDDA)NH2]-exendin-4 injected into patients with suspi-
cion of benign insulinomas that are hardly detectable or
not diagnosed by other available methods.
Materials and methods
Patients
Eleven patients (seven women and four men, mean age 48.0
±18.9 years, min. 16.0 years, max. 75.0 years) were enrolled
in this study. There were eight patients with clinical and
biochemical symptoms and signs of insulinoma, one patient
with malignant insulinoma, one patient with suspected local
recurrence of malignant insulinoma (MEN1) and one with
nesidioblastosis. All patients were verified for a positive
fasting test, elevated serum insulin and C-peptide level
concentrations (fasting glycaemia 33.0–54.0 mg/dl, fasting
insulinaemia 10.6–51.6 μIU/ml, C-peptide concentrations
4.7–6.3 ng/ml). None of the patients was treated with oral
antidiabetic agents. Symptoms of hypoglycaemia have been
observed for at least 1 year even up to 15 years in this group
of patients. The Department of Endocrinology, Jagiellonian
University Medical College in Cracow, Poland annually
diagnoses up to 30 patients with suspicion of insulinoma.
Because of difficulties in localizing the insulinoma focus by
standard diagnostic methods, five to six of them were sched-
uled for the study with labelled GLP-1 analogue annually.
Patients from other sites in Poland have also been diagnosed
in our department during the time when this study was
conducted.
Before GLP-1 receptor imaging, CT/MRI/EUS was per-
formed in all patients; eight patients underwent SRS after
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the injection of 99mTc-EDDA/HYNIC-TOC (Tektrotyd,
Polatom, Poland) and two patients positron emission tomog-
raphy (PET)/CT with 68Ga-DOTATATE. In all patients with
suspicion of benign insulinoma all these scans were nega-
tive or equivocal. It should be stated that in this group of
patients the negative or equivocal result of previous diag-
nostic studies was one of two main inclusion criteria to
perform the GLP-1 examination (after stated clinical symp-
toms of insulinoma). In the first patient with malignant
insulinoma the CT was positive in liver metastasis, but nega-
tive in the site of recurrence. In the second patient with
malignant insulinoma 68Ga-DOTATATE PET/CT was posi-
tive for liver and lymph node metastases, but negative for the
local recurrence. Detailed information about the patients is
presented in Table 1.
After receiving detailed information about the study pro-
cedure, all patients gave their written consent. The study
was approved by the local Ethics Committee.
Patients were placed on a liquid diet 1 day before the
beginning of the examination and fasted on the day of the
injection of the tracer. Each of them was carefully checked
for any adverse reactions. Because of the natural disease
course of insulinoma in fasting patients, blood pressure and
glucose values were monitored before and after injection of
the compound at several time points. Some of the patients
required glucose infusion at the time of the GLP-1 receptor
imaging procedure, because their level of glycaemia dropped
below 40 mg/dl.
After GLP-1 receptor imaging patients without contraindi-
cations qualified for a surgical treatment. The histopathological
confirmation of tumour presence and evaluation of its type was
performed after surgery.
Preparation of [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-
exendin-4
The radiolabelling of [Lys40(Ahx-HYNIC)NH2]-exendin-4
with 99mTc followed a two-vial kit formulation as previously
published [11] with some modifications [12]. Briefly, 1 ml
of a solution containing 30 mg (168 μmol) of tricine, 30 μg
of [Lys40(Ahx-HYNIC)NH2]-exendin-4 and 33.6 μg of
SnCl2 (12 μl of 22.2 mM SnCl2×2 H2O in 0.1 M HCl)
was filtered into a glass vial strictly under air protection, and
1 ml of a solution containing 10 mg of EDDA (pH was
adjusted to 7 with 1 M NaOH) was filtered into a second
glass vial. The glass vials were immediately frozen in liquid
nitrogen, lyophilized and closed afterward under nitrogen.
For labelling, the EDDA vial was reconstituted with 1 ml of
saline and 0.5 ml of it added to the [Lys40(Ahx-HYNIC)NH2]-
exendin-4 vial, followed by 740–1,850 MBq of 99mTcO4
- in
0.3–1.5 ml eluate of 99Mo/99mTc generator (Polatom, Poland)
and incubated for 10 min at 100 °C. After cooling to room
temperature, the reaction mixture was analysed by HPLC and
thin-layer chromatography (TLC). The average radiochemical
purity was more than 90 %. The mean injection activity for
patients was 740 MBq.
Imaging technique
GLP-1 receptor imaging with the use of [Lys40(Ahx-
HYNIC-99mTc/EDDA)NH2]-exendin-4 was performed at the
Nuclear Medicine Unit of the Endocrinology Department,
University Hospital in Cracow. Firstly, images were acquired
with a dual-head, large field of view E.CAM gamma camera
with low-energy high-resolution (LEHR) collimators. From
Table 1 Information about patients and examinations performed
Initials Age Sex Diagnosis Hypoglycaemia SRS CT GLP-1 Subsequent treatment
J.A. 57 F Ins. susp. 12 years − − + Surgery
R.G. 54 M Ins. susp. 1 year − − + Qualified for surgery
J.W. 16 M Ins. susp. 1.5 years − +/− + Surgery
A.P. 75 M Ins. susp. 4 years + − + Disqualified from
surgery
B.J. 38 F Ins. susp. 10 years 68Ga-DOTATATE − − + Surgery
K.S. 52 F Ins. susp. NA − + Surgery
M.K. 62 F Ins. susp. NA Not done − + Surgery
P.W. 21 M Ins. susp. NA + +/− + Surgery
A.K. 65 F Mal. ins. 4 years 68Ga-DOTATATE + in
liver meta and
lymph nodes
+ in liver meta, − in
recurrence place
− Pharmacotherapy
J.J. 57 F Mal. ins. 15 years − + in liver meta − in liver meta, +
in site of recurrence
Patient did not agree
to surgery
A.U. 31 F Nesidio NA + + + Surgery
F female, M male, NA not available, − negative result, + positive result, +/− equivocal result, Ins. susp. suspicion of insulinoma, Mal. ins.
malignant insulinoma, Nesidio nesidioblastosis
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2010 onwards all examinations were performed with the use
of the Symbia TruePoint T16 hybrid system, also with LEHR
collimators (Siemens Healthcare).
On the basis of the first patients’ examinations our intention
was to find the optimal acquisition protocol and to perform
dosimetric calculations. Due to this, initial whole-body scans
were carried out at six time points, from the first hour and in
some cases even up to 30 h (1, 2, 3, 6, 24 and 30 h) after the
injection of the compound. Standard camera settings (with
scan speed 12 cm/min for each examination) were used for
whole-body examinations with 99mTc [13].
Diagnostic single photon emission computed tomogra-
phy (SPECT) studies were performed at two time points,
between 3 and 4 h and between 5 and 6 h after the injection
of the tracer. The SPECT examinations were done with
standard camera settings like those used in the SRS study
after labelled somatostatin analogue injection [13]. The ac-
quired data were reconstructed using the ordered subset
expectation maximization (OSEM) FLASH 3-D iterative
reconstruction method. After the installation of the new
hybrid device in the Unit, SPECT/CT studies were carried
out in all subsequent patients with the same settings for the
SPECT part of the study and low-dose protocol for the CT part
(130 kV, 13mAs, slice thickness and reconstruction increment
5.0 mm).
In tumour tissue and kidneys, changes in the uptake were
evaluated over time. Volumetric analysis was performed to
assess the tumour to non-tumour ratio (T/nT ratio) and the
kidney to non-tumour ratio (K/nT ratio). The total counts in
defined regions of interest (ROI) were calculated. The back-
ground ROI was defined in the neighbouring normal tissue
for each region. T/nT and K/nT ratios were assessed for
SPECT scans performed between 2 and 3 h, 3 and 4 h, 5
and 6 h and 24 h (in two patients) after the injection of the
compound. The obtained images were assessed by two expe-
rienced nuclear medicine specialists.
Absorbed dose assessment
We also analysed biokinetic characteristics of the new tracer
and estimated the patient radiation dose. The organ radiation
dose was assessed for five patients. The external conjugate
view counting pair method was used for analysing whole-
body images [14]. Three source organs were chosen:
kidneys, liver and lungs. The area under the time-activity
curve for the whole body as well as the biological half-time
and the effective half-time for the tracer were estimated. The
organ absorbed dose coefficient D(rT, TD) was evaluated
according to the Medical Internal Radiation Dose (MIRD)
system [15][16]. The total effective dose, using weighting
factors defined in International Commission on Radiologi-
cal Protection (ICRP) publication 103, was also evaluated
[17]. The blood clearance of the tracer and the radiation
dose to the red marrow was established by the blood sam-
ples method [18]. The plasma and blood fractions were
measured separately. Urine samples were also collected
(after the 1 h scan and before 2 h, 3 h and 6 h scans). The
total volume of excreted urine and its activity was measured
after each collection.
Results
The quality of the obtained [Lys40(Ahx-HYNIC-99mTc/
EDDA)NH2]-exendin-4 images was evaluated as very good.
In eight of eight cases with suspicion of insulinoma, focal
uptake of the tracer in the pancreas was found (Fig. 1). In two
patients GLP-1 receptor scintigraphy was repeated because of
uncertain localization of the tracer in the pancreas. The second
study confirmed the previous foci localization. So far, suc-
cessful surgical excision of the tumour has been performed in
six patients. Post-surgical resolution of symptoms was ob-
served in all patients. Histopathological studies confirmed
type G1 neuroendocrine tumours. One patient is awaiting
surgery. One patient was disqualified from surgery due to
cardiological disorders. In one patient (38-year-old woman)
histopathological examination revealed the coexistence of
insulinoma and nesidioblastosis.
In the group of patients with benign insulinoma both
sensitivity and specificity of GLP-1 receptor imaging were
assessed as 100 %.
The first patient with confirmed malignant insulinoma
(65-year-old woman) was operated in 2007 due to a tumour
of the pancreatic tail. She was qualified for peptide receptor
radionuclide therapy (PRRT) in 2008, because of inoperable
liver metastases. A complete response to the therapy was
observed. However, in 2010 the patient presented again with
hypoglycaemia (below 35 mg/dl) and hyperinsulinaemia (up to
58.8 μIU/ml). PET imaging with 68Ga-DOTATATE was posi-
tive for liver and lymph node metastases. The patient was also
qualified for GLP-1 receptor imaging, which gave a negative
result. The patient is being treated with verapamil and up to
now symptoms of hypoglycaemia have not been observed any
more. In the other patient (57-year-old woman), who has been
suffering from MEN1 syndrome, the malignant insulinoma
was resected in 1996. Liver and lymph node metastases were
detected in 2010. GLP-1 receptor imaging confirmed the re-
currence of malignant insulinoma (a focal uptake in the place of
the removed pancreatic head), but uptake of neither GLP-1 nor
somatostatin receptor analogues was observed in metastatic
lesions. This patient did not agree to surgery.
Increased uptake of [Lys40(Ahx-HYNIC-99mTc/
EDDA)NH2]-exendin-4 in the upper abdomen (the result
similar to SRS) was seen in the case of a patient with nesidio-
blastosis (31-year-old woman) (Fig. 2). In this patient, after
three operations, each with partial pancreas resection, the
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observed focal accumulation of the tracer was necessary for
further verification. The patient underwent surgical treatment,
but died after the fourth surgery due to internal bleeding. The
histopathological examination confirmed insulinoma coexist-
ing with nesidioblastosis.
No adverse reactions such as nausea, decreased blood
pressure, bronchospasm, bradycardia, skin flushing or itching,
hives or other effects after the tracer injection were reported by
any of the patients at the time of the examination. Generally,
we did not observe exacerbation of hypoglycaemia related to
tracer injection, but this was difficult to verify in every patient
because of the natural disease course of insulinoma and the
necessity of a constant glucose infusion in most cases to
prevent the drop of glucose to levels which would be danger-
ous for the patient.
Changes in the average uptake in tumour tissue and
kidneys over time for the examined group of patients are
presented in Fig. 3.
As it was estimated for 111In-DOTA-exendin-4, the curve
for the plasma samples revealed a biexponential clearance
(a very fast alpha phase T1/2012 min and a visibly slower beta
phase T1/201 h 57 min) [9]. A low activity concentration was
also observed in blood samples, which probably was related to
the noneffective centrifugation or the contamination of samples
for the gamma counter measurements at the time of their
collection. The cumulated activity in the total volume of ex-
creted urine, which was measured up to 6 h post-injection,
revealed that the saturation of the curve was not reached.
Absorbed dose estimates are shown in Table 2.
Discussion
This paper presents our first experience with [Lys40(Ahx-
HYNIC-99mTc/EDDA)NH2]-exendin-4 in the detection of
the pancreatic neuroendocrine tumour secreting insulin, insu-
linoma. To the best of our knowledge, it is the first application
of this new compound in clinical practice. For most of the
patients involved in this study, examination with this novel
biomarker was the last hope for the localization of the insuli-
noma foci and further curative surgical treatment. We were
able to detect tumour lesions (benign insulinoma foci) with an
excellent sensitivity and specificity. The quality of images was
evaluated as high by referring physicians.
Malignant insulinomas frequently lack GLP-1 receptors
(positive GLP-1 receptor imaging only in 36 % of cases)
Fig. 1 Patient J.A. (57 years old) with clinically overt hypoglycaemia.
The examination with the GLP-1 analogue labelled with 99mTc revealed
focal accumulation of the tracer. The well-differentiated neuroendocrine
tumour type G1 was found in the histopathological study after surgical
excision of the part of the pancreas head selected during GLP-1 receptor
imaging study. a Fusion of GLP-1 receptor imaging and CTsagittal slice.
b Fusion of GLP-1 receptor imaging and CTaxial slice. c Fusion of GLP-
1 receptor imaging and CT coronal slice
Fig. 2 Patient A.U. (31 years old) with nesidioblastosis. The examina-
tion with the GLP-1 analogue labelled with 99mTc revealed focal accu-
mulation of the tracer in the pancreatic head. Insulinoma with coexisting
nesidioblastosis was confirmed in the histopathological examination after
surgery. a CTstudy. b Fusion of GLP-1 receptor imaging and CT. cGLP-
1 receptor imaging
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but, in contrast to benign insulinomas, more often express
SST2 receptors (positive SRS scan in 73 % of cases) [19].
This finding is very interesting because it shows the ability of
GLP-1 receptor imaging for predicting malignant or benign
status of an insulinoma lesion. There were only two patients in
our group with malignant insulinoma in whom GLP-1 scin-
tigraphy was performed. In one of them, GLP-1 receptor im-
aging confirmed the local recurrence of malignant insulinoma,
but no uptake of [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-
exendin-4 was observed in liver metastases. This case might
suggest the different biology of primary lesions and their me-
tastases in terms of the expression of GLP-1 receptors. This
phenomenon is well known for somatostatin receptors in neu-
roendocrine tumours [20].
According toWild et al., hypoglycaemia after 111In-DTPA-
exendin-4 (10±2 μg) injection is observed in patients with
malignant insulinoma [19]. The decrease of blood glucose
level was more often seen in cases of patients with GLP-1
receptor-positive lesions than in those with negative ones. The
mechanism of this phenomenon is unclear, as is the mecha-
nism of possibly more severe hypoglycaemia occurring after
cold somatostatin analogue injection in patients with malig-
nant insulinoma. It is probably caused by the inhibitory effect
of the somatostatin analogue on glucagon excretion [21]. In
the cases of insulinoma patients enrolled in our study it was
difficult to assess the changes in glucose levels related only to
the labelled GLP-1 injection because some of them received
constant glucose infusion to prevent hypoglycaemia. Based
on our experience, we believe that establishing this fact is a
very difficult task, due to the natural disease course of insuli-
noma. Because of significant differences in the patients’ con-
ditions before the examination, each patient needed to be
managed individually.
Nesidioblastosis is another clinical challenge. The patho-
genesis of this disease still remains unclear. An increased
expression of insulin-like growth factor 2 receptor (IGF2R),
insulin-like growth factor 1 receptor alpha (IGF1Rα) and trans-
forming growth factor beta receptor type 3 (TGFβR3) was
observed in samples containing pancreatic islets from patients
suffering from nesidioblastosis. It seems that certain growth
factors and growth factor receptors may significantly contribute
to the development of nesidioblastosis [22]. Reubi et al. eval-
uated in vitro the GLP-1 receptor status of pancreatic tissues
collected from patients suffering from hyperinsulinaemic hypo-
glycaemia, specifically after gastric bypass surgery. In this
study the overexpression of the GLP-1 receptor was not found
on the pancreatic islet cell surface. Thus, according to the
authors, patients with post-gastric bypass hyperinsulinaemic
hypoglycaemia should not be examined with GLP-1 receptor
imaging in vivo [23]. However, in clinical practice it should be
expected that insulinoma may coexist with nesidioblastosis.
Recurrent hypoglycaemias even after surgical resection of
70 % of the pancreas in patients with nesidioblastosis may
suggest the presence of insulinoma [24]. In the patient with
nesidioblastosis examined with labelled GLP-1 receptor ago-
nist in our department, accumulation of the tracer was observed
in the pancreatic area. In this patient histopathological exami-
nation confirmed coexistence of insulinoma and nesidioblas-
tosis. Moreover, in one patient suspected of having insulinoma
(38-year-old woman), histopathological examination also
revealed a microadenoma of the pancreatic head (in the local-
ization of the focal uptake of GLP-1) and coexisting nesidio-
blastosis. These findings support the statement that, despite
similar symptoms resulting from hyperinsulinaemia and hypo-
glycaemia, the pathogenesis of nesidioblastosis may vary sig-
nificantly depending on the patient’s clinical history and may
cause lots of problems for clinicians. The other conclusion is
that because of difficulties in the management of patients with
nesidioblastosis and the potential coexistence of insulinoma
and nesidioblastosis, physicians should include GLP-1 receptor
imaging as a diagnostic possibility for these patients.
Fig. 3 Tumour to non-tumour ratio (T/nT) and kidney to non-tumour
ratio (K/nT) over time (means ± SD). The T/nT remained relatively
stable over time, while the K/nT decreased visibly (~ 40 % from the
time of injection to 6 h after injection)
Table 2 Organ absorbed dose estimates for [Lys40(Ahx-HYNIC-99mTc/
EDDA)NH2]-exendin-4
Organ Mean estimated absorbed dose ± SD
(mGy/MBq)
Kidneys 0.1124±0.0526
Liver 0.0055±0.0009
Lungs 0.0036±0.0007
Spleen 0.0052±0.0023
Pancreas 0.0043±0.0017
Intestine 0.0066±0.0026
Red marrow 0.0052±0.0010
Thyroid 0.0001±0.0000
Muscles 0.0009±0.0003
Ovaries 0.0005±0.0004
Total body 0.0027±0.0010
Effective dose (mSv/MBq) 0.0024±0.0003
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It should be highlighted that the use of image fusion was
mandatory for proper diagnosis in all cases. In some cases the
fusion of GLP-1 receptor scintigraphy and CT/MRI enables
visualization of small lesions not reported in CT/MRI before.
In our group of patients in two cases a focal lesion was found
on repeat CT/MRI scans following a positive result of GLP-1
receptor scintigraphy.
Despite the fact that a high kidney uptake was visible in all
cases, the image quality was excellent and tumour foci were
very well visible with a high T/nT ratio. Background uptake
over the whole body was low with the exception of the
kidneys, which were strongly labelled owing to renal excre-
tion of the compound. The same finding was reported for
111In-DOTA-exendin-4. Therefore, as it was suggested for
GLP-1 receptor imaging with 111In, additional delayed images
should be performed in patients with negative early scans
[10]. For optimizing the acquisition protocol, Gelofusine,
fragmented albumin or other substances should be used for
blocking tracer uptake by proximal kidney tubules [11, 25].
Recently, PET imaging radiotracers labelled with 68Ga and
18F, targeting GLP-1 receptors, have also been developed
{[Lys40(Ahx-DOTA-68Ga)NH2]exendin-4, [Lys
40(68Ga-
DOTA)]exendin-3 and 18F-FBEM-EM3106B} [11, 26, 27].
The potential of novel biomarkers based on GLP-1 analogues
suitable for PET examinations has been tested only in animal
models until now. Because of different advantages and dis-
advantages of all GLP-1 targeting tracers (labelled with 99mTc,
111In, 68Ga or 18F) today it is a matter of argument which of
them will be the best for detecting insulinomas in humans.
Unquestionably, the GLP-1 receptor tracer labelledwith 99mTc
is characterized by the general availability of the isotope,
lower radiation exposure to patients and staff, and potential
usefulness of this compound for intraoperative localization of
insulinoma foci using a gamma probe [11]. It is possible that
all of them (no matter which radionuclide the GLP-1 analogue
is conjugated with) will present the same very high sensitivity
and specificity related to an extremely high density of GLP-1
receptors on benign insulinoma cell surface. Nowadays there
is a lack of comparative studies with the use of different GLP-
1 radiopharmaceuticals injected into the same patients. In the
near future such examinations (based on exendin-4 labelled
with 99mTc, 68Ga and 111In) are planned. However, taking into
account the very high sensitivity of this method the registra-
tion by national authorities of the labelled compound based on
GLP-1 analogues might be considered in cases of patients
with suspected benign insulinoma in the nearest future. More-
over, it is well known that there are other tumours overex-
pressing GLP-1 receptors; therefore, the next natural step
should be the use of labelled GLP-1 analogues in cases of
tumours other than benign insulinoma. In the clinical trial
conducted in our department this tracer was used successfully
for visualization of medullary thyroid cancer and phaeochro-
mocytoma (unpublished data).
In this paper the biokinetics and initial dose assessment
of [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 for
SPECT/CT studies were also addressed. The average effec-
tive dose is comparable with the radiation dose to patients
after SRS performed with 99mTc-EDDA/HYNIC-Tyr3-
octreotide [28, 29]. Wild et al. evaluated the pharmacoki-
netics and radiation dose to patients after injection of
[Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 in an
animal study [11]. Comparing the biokinetics, our study
showed a faster retention of the tracer in human organs
assumed to be radiation sources. For organ radiation doses
and the effective dose, similar levels of these values were
calculated, except for the kidneys (an about twofold higher
absorbed dose was calculated in our study). These data
should be considered only as the basis for further evaluation
of radiation safety of this radiopharmaceutical.
Conclusion
GLP-1 receptor scintigraphy is a promising diagnostic tool for
patients with clinical symptoms of insulinoma. It enables the
localization of even very small tumours with excellent sensi-
tivity and specificity, and proper imaging is the most impor-
tant step for successful surgery and complete patient recovery.
Despite some difficulties to overcome, the new compound
seems to be an effective new tracer for clinical practice and
appears to be safe for the patient.
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